Novocure (NVCR) Secures $400M Multi-Tranche Non-Dilutive Debt Financing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
NovoCure Ltd. (NVCR) PT Lowered to $14.50 at Evercore ISI
May 2, 2024 4:48 PM EDTEvercore ISI analyst Vijay Kumar lowered the price target on NovoCure Ltd. (NASDAQ: NVCR) to $14.50 (from $15.00) while maintaining a In Line rating.
The analyst comments "NVCR reported headline revs of $139 MM, up +13% y/y (vs -11% comp) with total revs coming in slightly above ST. Total revs incl ~$4.2 MM from prior period claims in U.S., ex which magnitude of the Beat was ~3%. Active patients and TRx both grew... More
